30389923 |
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Vellano, CP,
Scott, KL,
Ju, Z,
Jeong, KJ,
Shao, SH,
Leonard, PG,
Woessner, R,
Mills, GB,
Sahni, N,
Ip, CKM,
Hua, X,
Ng, PKS
|
Nat Commun |
2018 |
12660384 |
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
Marynen, P,
Boogaerts, M,
Griffin, JD,
Galinsky, I,
Cortes, J,
Coutré, SE,
Kantarjian, H,
Schmid, J,
Malone, J,
Schrier, SL,
Cools, J,
Stover, EH,
Wlodarska, I,
Kutok, J,
Rose, M,
Verhoef, G,
Vandenberghe, P,
Gotlib, J,
Gilliland, DG,
Alam, R,
Clark, J,
Legare, RD,
Cross, NC,
Stone, R,
Deangelo, DJ,
Tefferi, A
|
N. Engl. J. Med. |
2003 |
22665524 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors
Fletcher, JA,
Mariño-Enríquez, A,
Heinrich, MC,
Donsky, RS,
Presnell, A,
Griffith, DJ,
McKinley, A,
Liang, CW,
Patterson, J,
Taguchi, T
|
Mol. Cancer Ther. |
2012 |
15928335 |
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib
Shiraga, S,
McGreevey, L,
Schroeder, A,
Corless, CL,
Heinrich, MC,
Harrell, P,
Morich, J,
Bainbridge, T,
Town, A,
Griffith, D
|
J. Clin. Oncol. |
2005 |